Erratum
Free Access
Erratum
First published: 06 April 2018
In 1, the data under the fifth column ‘LS mean change from baseline (95% CI)’, 1st and 2nd entries of row ‘HbA1c (%)’ of Table 3 were published incorrectly. The corrected Table 3 is shown below.
| Treatment (n) | Baseline | Endpoint | LS mean change from baseline (95% CI) | Difference (95% CI) in LS mean change from baseline | P-value | |
|---|---|---|---|---|---|---|
| HbA1c (%) | LM25 (72) | 8.6±1.1 | 7.1±0.8 | -1.55 (-1.73, -1.36) | 0.48 (0.22, 0.74) | <0.001 |
| LM50 (69) | 8.5±1.1 | 6.5±0.6 | -2.03 (-2.21, -1.84) | |||
| FBG (mmol/L) | LM25 (80) | 9.6±2.3 | 7.2±1.6 | -2.50 (-2.89, -2.11) | -0.38 (-0.94, -0.18) | 0.180 |
| LM50 (76) | 9.7±2.3 | 7.6±1.8 | -2.12 (-2.53, -1.72) | |||
| 1,5-AG (μg/mL) | LM25 (80) | 5.16±4.43 | 10.24±8.30 | 5.03 (3.49, 6.57) | -2.72 (-4.92, -0.52) | 0.016 |
| LM50 (76) | 5.75±5.60 | 12.99±6.56 | 7.75 (6.16, 9.34) |
- Unless indicated otherwise, data are given as the mean ± SD.
- 1,5-AG, 1,5-anhydroglucitol; CI, confidence interval; FBG, fasting blood glucose; LM25, insulin lispro mix 25; LM50, insulin lispro mix 50; LS, least squares; T2DM, type 2 diabetes mellitus.
The corresponding in-text citation on page 578-579 has been corrected and the statement should read as follows:
“The decrease from baseline in mean HbA1c levels was significantly higher in the LM50 treatment group (LS mean change –2.03 %; 95 % CI -2.21, -1.84; P< 0.001) than in the LM25 treatment group (LS mean change -1.55%; 95 % CI -1.73, -1.36) at Week 26 (Table 3).”
The authors apologize for this error and regret any inconvenience it may have caused.
